| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
V-01 is a protein subunit COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc.[1][2][3]
- ^ "China approves clinical trials for Livzon Pharma unit's COVID-19 vaccine". Reuters. 23 March 2021. Retrieved 21 April 2021.
- ^ "评价重组新型冠状病毒融合蛋白疫苗在健康人群免疫原性和安全性随机、双盲、安慰剂对照的II期临床试验" [A randomized, double-blind, placebo-controlled phase II clinical trial evaluating the immunogenicity and safety of a recombinant novel coronavirus fusion protein vaccine in healthy people]. chictr.org.cn (in Chinese). Chinese Clinical Trial Registry. Retrieved 21 April 2021.
- ^ "评价重组新型冠状病毒融合蛋白疫苗在健康人群安全性和免疫原性随机、双盲、安慰剂对照的I期临床试验" [A randomized, double-blind, placebo-controlled phase I clinical trial evaluating the safety and immunogenicity of a recombinant novel coronavirus fusion protein vaccine in healthy people]. chictr.org.cn (in Chinese). Chinese Clinical Trial Registry. Retrieved 21 April 2021.